APA (7th ed.) Citation

DM, B., MN, P., F, M., A, R., K, G., F, W., . . . K, P. (2024). Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: A multicentre, prospective observational study from the RESPOND consortium cohorts. The lancet. HIV, 11(5), e321. https://doi.org/10.1016/S2352-3018(23)00328-4

Chicago Style (17th ed.) Citation

DM, Byonanebye, et al. "Associations Between Change in BMI and the Risk of Hypertension and Dyslipidaemia in People Receiving Integrase Strand-transfer Inhibitors, Tenofovir Alafenamide, or Both Compared with Other Contemporary Antiretroviral Regimens: A Multicentre, Prospective Observational Study from the RESPOND Consortium Cohorts." The Lancet. HIV 11, no. 5 (2024): e321. https://doi.org/10.1016/S2352-3018(23)00328-4.

MLA (9th ed.) Citation

DM, Byonanebye, et al. "Associations Between Change in BMI and the Risk of Hypertension and Dyslipidaemia in People Receiving Integrase Strand-transfer Inhibitors, Tenofovir Alafenamide, or Both Compared with Other Contemporary Antiretroviral Regimens: A Multicentre, Prospective Observational Study from the RESPOND Consortium Cohorts." The Lancet. HIV, vol. 11, no. 5, 2024, p. e321, https://doi.org/10.1016/S2352-3018(23)00328-4.